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HIGHLIGHTS 
• Overall survival rates correlate with different AFP and LDH levels but not with HCG levels within 
the intermediate prognosis category according to IGCCCG. 
• The majority of patients with intermediate prognosis and nonseminomatous histology expect a 
5-year OS rate of ∼89% which is almost similar to the good prognosis category. 
• A small fraction of patients with LDH values >3 UNL and/or AFP > 6,000 IU/ml reflect a high risk 
population with impaired outcome. The optimal management of these patients warrants further 
investigations. 
 
ABSTRACT 
BACKGROUND 
Germ cell tumor patients with intermediate prognosis (IPGCT) according to the International Germ 
Cell Cancer Collaborative Group (IGCCCG) classification represent a heterogeneous group with 
different clinical features. This analysis was performed to investigate the prognostic impact of 
different tumor marker levels prior to first line chemotherapy within IPGCT. 
METHODS 
For this study an international registry for IPGCT was established. Eligibility criteria were 
intermediate prognosis according to IGCCCG criteria, nonseminomatous histology, male sex, and 
age ≥ 16 years. Uni- and multivariate analysis were conducted to identify characteristics 
associated with survival outcomes. Receiver-Operating-Characteristic curve analysis was applied 
to find cut-off parameters. Five-year overall survival (OS) rate was the primary and 5-year 
progression-free survival rate the secondary endpoint. 
RESULTS 
This database included 634 IPGCT with a median follow-up of 9.0 years (interquartile range: 
14.35). Patients received first line treatment with platinum based chemotherapy, associated with 
a 5-year OS rate of 87%. The stratification of patients according to AFP levels revealed a 
correlation between AFP levels and outcome, associated with 5-year OS rates of 88% for AFP 
levels <1,000 IU/ml (n = 303), 89% for 1,000 to 2,000 IU/ml (n = 82), 87% for >2,000 to 6,000 IU/ml 
(n = 121), and 82% for >6,000 IU/ml (n = 57) prior first course of chemotherapy, respectively (P= 
 
 
0.013). LDH levels prior fist course of chemotherapy also correlated with outcome associated with 
5-year OS rates of 92% for <2 UNL (n = 271), 89% for ≥2 to 3 UNL (n = 85), 78% for >3 to 4 UNL 
(n = 34), and 77% for >4 UNL (n = 79), respectively (P= 0.03). Different HCG levels prior 
chemotherapy were not associated with outcome. In multivariable analysis AFP levels >6,000 
IU/ml (P= 0.023; hazard ratio HR 2.263) or >1,982 IU/ml (P= 0.031; HR 1.722), and LDH levels 
>3 UNL (P< 0.001; HR 2.616) were independent prognosticators for OS. 
CONCLUSIONS 
Prognostication according to LDH and AFP levels prior chemotherapy could offer a new approach 
to stratify patients within the intermediate prognosis cohort. According to our findings, patients 
with AFP values above 6,000 IU/ml or/and LDH > 3 UNL represent an independent high risk 
cohort. 
Our results need to be confirmed in the upcoming IGCCCG reclassification. 
Keywords: AFP and LDH levels; IGCCCG classification; Intermediate prognosis; Risk factor 
stratification. 
 
GRAPHIC ABSTRACT  
 
 
 
 
 
 
 
1. INTRODUCTION 
The prognostic factor-based staging classification for patients with metastatic germ cell 
tumors (GCT), introduced in 1997 by the International Germ Cell Cancer Collaborative 
Group (IGCCCG) relies on data from the 1970s to 1980s [1]. This system stratifies 
patients into good, intermediate, or poor prognosis categories based on different patient 
characteristics such as histology, tumor marker levels in case of nonseminomatous 
histology and metastatic sites at first diagnosis. The good, intermediate, and poor 
prognosis categories were initially associated with 5-year OS rates of 91%, 79%, and 
48%, respectively and standard treatment for the intermediate and poor prognosis 
category has remained BEP with application of four cycles [2], [3], [4], [5]. Nowadays, 
these data seems outdated as recent analyses suggest that outcome improved 
remarkably for each risk group over the last decades [6], [7], [8]. Moreover, current 
analysis revealed no significant difference concerning the outcome between good and 
intermediate prognosis category, which further questions the applicability of the IGCCCG 
classification for GCT patients with intermediate prognosis (IPGCT) [6]. Secondary, 
similar treatment approaches for intermediate- and poor prognosis patients may result in 
overtreatment for some IPGCT [9]. Hence, the definition of clinical characteristics with 
prognostic impact within the intermediate prognosis category may assist to better 
estimate outcomes and could improve individual treatment decision-making based on a 
novel stratification system. As indicated in our previous works, AFP and LDH cut-off levels 
prior first line chemotherapy were prognosticators within IPGCT [8], [9]. To examine the 
association between outcome and different tumor marker levels for IPGCT with 
nonseminomatous histology in more detail, a patient stratification system according to 
different tumor marker levels was established. 
2. PATIENTS AND METHODS 
2.1. STUDY POPULATION 
Altogether 14 centers across Europe, the Russian Federation, USA and Australia 
participated, after initiation of this project within the global GCT collaborative group (G3). 
After approval by the local ethics committee, clinical information was collected 
retrospectively. 
 
 
2.2. INCLUSION CRITERIA 
This analysis included nonseminomatous IPGCT according to the IGCCCG risk 
classification. Inclusion criteria were intermediate prognosis according to IGCCCG 
criteria, nonseminomatous histology, male sex, and age ≥ 16 years. Patients were first 
diagnosed and received treatment from 1980 to 2014. 
2.3. STATISTICAL ANALYSIS 
It was the objective of this project to prove different marker levels to be associated with 
outcome and to test the correlation between rising tumor marker levels (AFP, LDH, and 
HCG), and prognosis within IPGCT with nonseminomatous histology. Primary end-point 
was the 5-year overall survival (OS) rate defined as the percentage of people in our 
population who are alive 5 years after their primary diagnosis or treatment initiation. 
Secondary endpoint was the 5-year progression-free survival (PFS), defined as the time 
from treatment initiation until disease progression or death due to disease. Patients lost 
to follow-up were censored at the date of last visit. The following patient characteristics 
were evaluated as potential prognostic factors: histology of the primary tumor, presence 
/ absence of metastases to the following organs e.g., lymph node involvement, lung 
involvement, localization of the primary tumor (gonadal vs. extragonadal), AFP, HCG, and 
LDH levels prior first line of chemotherapy. 
Calculation of correlations between subgroups was performed by χ2 test. Survival 
analysis was conducted using the method of Kaplan-Meier [10]. The log-rank test was 
applied to compare survival estimates, and multivariate Cox regression analysis was used 
in multivariate models. For patients characteristics that displayed a trend to be associated 
with OS and/or PFS with a P value of ≤0.1 multivariate analysis was performed to confirm 
these factors as independent prognosticators. Results were considered statistically 
significant with a two-sided P value <0.05. Statistical analyses were conducted using 
SPSS software version 24. 
3. RESULTS 
In total, 634 IPGCT with a median follow-up of 9.0 years (interquartile range [IQR]: 14.35) 
were eligible for this retrospective analysis. Patients were diagnosed from 1980 to 2014. 
 
 
Altogether 107 patients were first diagnosed in the 1980s (17%), 140 patients in the 1990s 
(22%), and 387 patients were diagnosed since 2000 (61%). 
3.1. CLINICAL CHARACTERISTICS 
The median age was 31 years (range: 16–62). At first diagnosis, 246 (39%) patients were 
staged as UICC stage II A–C, and 368 (58%) as UICC stage III A–C, respectively. For 20 
patients (3%) the exact stage was missing. Median levels of tumor markers prior 
chemotherapy were: AFP 700 IU/ml (IQR: 2,521; 25% percentile 33.4; 75% percentile 
2,550), HCG 343 U/l (IQR: 4,978; 25% percentile 21.3; 75% percentile 5,000), and LDH 
716 U/l (IQR: 861 25% percentile 397.5; 75% percentile 1,258.3). Altogether n = 303 
patients had AFP levels of <1,000 IU/ml. These patients were considered to be part of 
the intermediate prognosis category due to LDH levels >1.5 UN in 278 cases and/or 
elevated HCG levels with another 56 cases. Patient characteristics are reported in Table 
1. 
Table 1. Patient characteristics. 
Characteristics Absolute number of patients n = 634 % 
Primary testicular 585 92 
Extragonadal retroperitoneal 48 8 
Organ involvement: 
Lymph nodes 469 74 
Lungs 198 31 
Stage UICC: 
IIa–c 246 39 
IIIa–c 368 58 
Not available 22 3 
Years of first diagnosis: 
1980s 107 17 
 
 
1990s 140 22 
2000 387 61 
Best response to first line: 
Responder (CR/PR−) 523 82 
No change 14 2 
Progressive disease 10 2 
Not available 87 14 
Secondary surgery after chemotherapy 226 36 
 
3.2. TREATMENT 
First-line chemotherapy was conducted according to the BEP regimen in 619 (98%) 
patients, including 6 patients treated with T (paclitaxel)-BEP and 3 patients receiving 
dose-intensification after 2 cycles BEP according to the SWENOTECA Protocoll [11]. One 
patient received VIP (cisplatin, etoposide, and ifosfamide). In 8 patients (1%), the exact 
treatment regimen was not described. Patients received a median of 1 (range: 1-8) 
treatment line.: first line chemotherapy was performed with 4 cycles in 495 patients of 
platinum based chemotherapy; 45 patients received 3 cycles and 61 five to six cycles, 
respectively. Altogether 14 patients received less than 3 cycles. 
Information concerning best response was available in 552 patients (87%). Of these, 185 
patients (33%) achieved a complete remission defined as normal tumor marker levels and 
no radiological signs of disease ≥1cm. With 338 patients (62%), the majority achieved a 
marker negative partial remission defined as normal tumor markers levels and a decrease 
of tumor masses ≥30% compared to baseline but with ≥1cm residual masses. In 8 
patients (1%), a marker positive partial remission was described defined as elevated 
tumor markers levels and residual disease with ≥30% decrease compared to baseline but 
with ≥1cm residual masses. Furthermore stable disease/no change was described in 6 
(1%) and progressive disease (PD) defined as increase of tumor markers levels (AFP or 
 
 
HCG) after 2 sequential evaluations within 2 weeks; tumor growth or new lesions (growing 
teratoma syndrome excluded), occurred in 10 patients (2%). 
Of the 338 patients with marker negative partial remission, 226 patients (67%) received 
secondary surgery and 112 patients (33%) underwent no further resections. The majority 
of the surgical interventions specified were lymphnode dissections of the retroperitoneum. 
Surgical procedures performed were as follows: lymphnode dissections of the 
retroperitoneum in 128 patients and/or, resection of lung metastases in 24 patients 
and/or, orchiecomty after chemotherapy in 5 patients. For 69 patients, the exact surgical 
intervention was not exactly specified. 
By the comparison of treatment responders with versus without secondary surgery, the 
5-year OS rate and of patients with vs. without secondary surgery was 85% vs. 86%, 
respectively (P= 0.364). The 5-year PFS rate was 78% with secondary surgery vs. 55% 
without secondary surgery; respectively (P<0.001). 
Altogether 151 patients (25%) relapsed after first line treatment. These patients received 
further treatment lines. Patients with relapse received further treatment lines. Second line 
chemotherapy consisted of conventional dosed salvage regimens with VIP in 33 and TIP 
in 19 cases. In 6 cases, the name of second treatment line was unknown. In 14 cases, 
high dose chemotherapy with autologous stem cell transfusion was performed in the 
second line. 
3.3. OUTCOME 
The 5-year OS and PFS rate was 87% and 81%, respectively. The 5-year OS survival 
rates stratified according to the time period of first diagnosis were 81% for patients 
diagnosed from 1980 to 1986, 85% for patients diagnosed from 1987 to 1996, 88% for 
patients diagnosed from 1997 to 2005, and 91% for patients diagnosed since 2006, 
respectively. 
3.4. RISK FACTOR ANALYSIS FOR OS 
A stratification of patients according to AFP levels of <1,000 IU/ml (n = 303), 1,000 to 
2,000 IU/ml (n = 82), >2,000 to 6,000 IU/ml (n = 121), and >6,000 (n = 57) IU/ml prior first 
 
 
course of chemotherapy, revealed a correlation between AFP levels and outcome, 
associated with 5-year OS rates of 88%, 89%, 87%, and 82%, respectively (P= 0.013) 
(Fig. 1). A patient stratification according to LDH levels <2 UNL (n = 271), ≥2 to 3 UNL 
(85), >3 to 4 UNL (n = 34), and >4 UNL (n = 79) prior chemotherapy also correlated with 
OS associated with 5-year OS rates of 92%, 89%, 78%, and 77%, respectively (P= 0.03) 
(Fig. 2). In univariable analysis AFP levels >6,000 IU/ml (P= 0.004) and LDH levels >3 
UNL (P< 0.001) correlated with an impaired OS. ROC curve analysis revealed the AFP 
value of 1,982 IU/ml as significant cutpoint concerning death events with a 5-year OS rate 
of 86% vs. 88% (P= 0.028). Rising HCG levels did not correlate with outcome in this 
patient population (Fig. 4). 
 
Fig. 1. OS of patients with intermediate prognosis according to initial AFP levels. 
 
 
 
Fig. 2. OS of patients with intermediate prognosis according to initial LDH levels. 
 
Fig. 4. PFS of patients with intermediate prognosis according to initial AFP levels. 
In multivariable analysis AFP levels >6,000 IU/ml (P= 0.023; HR 2.263) or >1,982 IU/ml 
(P= 0.031; HR 1.722) and LDH levels >3 UNL (P< 0.001; HR 2.161) were confirmed as 
independent prognosticators for OS (Table 2). 
 
 
Table 2. Results of univariate and multivariate analyses of PFS and OS. 
Factor P value 5-year PFS P value 5-year OS 
LDH >3 UNL vs. LDH <3 UNL 0.659 (79% vs. 85%; 95% CI 
262.3–293.7) 
<0.001 (80% vs. 88%; 95% CI 
301.2–325.6) 
AFP >6,000 IU/ml vs. ≤6,000 <0.001 (70% vs. 84%; 259.7–
288.8) 
0.004 (92% vs. 88%; 95% CI 
294.3–319.5) 
Embryonal vs. nonembryonal 0.332 (80% vs.84%; 95% CI 
259.7–289.6) 
0.179 (86% vs. 90%; 95% CI 
298–322) 
HCG levels <5,000 vs. 5,000–
1,000 vs. >1,000 
0.439 (92% vs.73% vs.76%; 95% 
CI 198.1–232.5) 
0.236 (88% vs. 82% vs.92%; 
95% CI 280.5–212.3) 
Chorion vs. nonchorion 0.815 (79% vs. 83%; 95% CI 
260.3–290.2) 
0.204 (83% vs. 90%; 95% CI 
300.5–325.0) 
UICC stage II vs. III 0.717 (81% vs. 82%; 95% CI 
257.5–285.8) 
0.249 (90% vs. 85%; 95% CI 
296.1–320.0) 
Lymphnode metastases vs. 
none 
0.485 (81% vs.79%; 95% CI 
260.3–289.4) 
0.620 (89% vs. 87%; 95% CI 
299.5–323.2) 
Lung metastases vs. none 0.641 (81% vs. 82%; 95% CI 
260.3–289.4) 
0.671 (88% vs. 87%; 95% CI 
299.5–323.2) 
Teratoma vs. no teratoma 0.253 (73% vs.83%; 95% CI 
161.1–179.7) 
0.698 (90% vs. 92%; 95% CI 
185.6–199.4) 
Gonadal vs. extragonadal 0.202 (78% vs. 83%; 95% CI 
257.7–285.7) 
0.757 (87% vs. 86%; 95% CI 
296.8–320.3) 
Yolk sac vs. no yolk sac 0.797 (82% vs. 82%; 95% CI 
261.1–290.9) 
0.793 (87% vs. 88%; 95% CI 
301.4–325.7) 
 
Results of multivariable Cox analyses of OS 
 
Factor OS (months) 
 
HR 95% CI P value 
AFP level > 6,000 IU/ml 2.263 1.119–4.577 0.023 
 
 
LDH > 3.0 UNL 2.616 1.621–4.221 <0.001 
 
Patients with AFP levels >1982 IU/ml had a higher risk of disease recurrence (recurrence 
rate: 20% vs. 31%; P= 0.02) as did patients with LDH levels >2 UNL (recurrence rate: 
29% vs. 42.5%; P= 0.047). 
The 5-year OS rate of patients with HCG levels from 0 to 5,000 U/l; 5,001 to 10,000 U/l 
and >10,000 U/l was 88%, 82%, and 91% (P= 0.236). 
3.5. RISK FACTOR ANALYSIS FOR PFS 
The patient stratification according to AFP levels <1,000 IU/ml, 1,000 to 2,000 IU/ml, 
>2,000 to 6,000 IU/ml and >6,000 IU/ml prior first course of chemotherapy was also 
significantly correlated with the PFS, associated with 5-year PFS rates of 86%, 84%, 83%, 
and 68%, respectively (P= 0.01) (Fig. 3). AFP cut-off value >6,000 IU/ml was also 
associated with an impaired 5-year PFS rate with 70% vs. 84% (P< 0.001). LDH levels 
prior chemotherapy, did not correlate with PFS (P= 0.659). Further results of statistical 
analysis are displayed in Table 2. There was no correlation with HCG levels stratified 
according to levels from 0 to 5,000 U/l; 5,001 to 10,000 U/l, and >10,000 U/l, and PFS 
(P= 0.439) 
 
Fig. 3. AFP level of 1982 IU/mL as single cut-off variable concerning outcome. 
 
 
4. DISCUSSION 
The IGCCCG classification reveals a heterogenous cohort of patients with different 
histologic features and varying tumor marker levels before treatment 
initiation [2], [3], [4], [5]. Approximately 26% of the patients belong to the intermediate 
prognosis category. Defined by the presence of either AFP values of 1.000 to 10.000 
IU/ml, HCG levels of 5.000 to 50.000 IU/l, LDH levels between 1.5 and 10 times the upper 
limit of normal range for nonseminomatous gonadal and retroperitoneal primary tumors, 
or the presence of nonpulmonary visceral metastases for those with pure seminoma, 
IPGCT represent a very heterogenous cohort. While AFP and LDH cut-off values were 
previously described to be associated with OS [8], [9], this analysis was performed to 
characterize the prognostic impact of different LDH and AFP levels and tumor marker 
constellations prior first line chemotherapy. In our analysis, a 5-year OS rate of 87% could 
be achieved, which is superior to the description of previous IGCCCG data. Improved 
outcome of GCT patients was already reported within other studies [11], [12], [13]. We 
suppose that outcomes of advanced GCT patients signficantly improved over the last 
decades, due to improved treatment conditions including dose density, better supportive 
care, and salvage treatment options for relapsed disease. 
As outcome of IPGCT was currently described to be equivalent to the good prognosis 
category, the actuality and reliability of the IGCCCG-defined IPGCT category becomes 
questionable. Consequently, the implementation of new prognosticators could help to 
realize treatment decisiond based on individual risk factor assesment. In this analysis we 
found a correlation between rising marker levels and imaired outcome concering OS for 
different LDH and AFP values. Here patients with AFP values >6,000 IU/ml and LDH > 3 
UNL revealed an outcome similar to the poor prognosis category and therefore differ 
greatly from other IPGCT. 
Our results demonstrate that the intermediate prognosis category represents a 
heterogenous cohort according to different prognosticators. For patients with high marker 
levels, further investigations concerning optimal treatment strategies are needed. 
Our analysis has several limitations due to its’ retrospective design including partially 
missing data, and tumor marker levels edited by different laboratories around the world. 
 
 
Further sources of error are a patient cohort treated in a time period of almost 40 years, 
as well as treatment performed in different parts of the world with different health systems. 
Central review concerning tumor markers and histology was not performed. 
Nonetheless, we think that our data can provide reliable information for the optimal risk 
factor stratification for IPGCT which can depend on different LDH and AFP values. 
We expect that the EORTC-led IGCCCG update initiative to give us further information 
how to deal with different marker constellation within different prognostic groups. 
Furthermore, new approaches such as miRNAs as novel tumor markers for GCT patients 
will hopefully improve diagnosis, risk stratification, and treatment of GCT patients [14]. 
5. CONCLUSIONS 
Prognostication according to LDH and AFP levels prior chemotherapy may offer a new 
approach to stratify the heterogeneous group of nonseminomatous IPGCT. The largest 
fraction of our patients had AFP levels <6,000 IU/ml and LDH < 3 UNL associated with 
an outcome similar to those in the good prognosis, while patients with tumor marker levels 
>6,000 IU/ml and/or >3 UNL display a high risk group. The optimal treatment of these 
patients warrants further investigations. Our results need to be confirmed in the upcoming 
IGCCCG reclassification. 
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